Skip to main content

Advertisement

Log in

Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

The aim of this trial was to evaluate the safety and efficacy of oxaliplatin and capecitabine (XELOX) in neuroendocrine tumours’ (NETs) treatment.

Methods

Forty patients (pts) with advanced NETs were treated. Of these, 13 had untreated poorly differentiated NETs, 27 had well-differentiated NETs in progression after somatostatin analogues. Patients received oxaliplatin e.v. 130 mg/mq i.v. and capecitabine 2,000 mg/mq/die. The primary sites of the disease were: lung (10 pts), pancreas (15 pts), small bowel (8 pts), unknown (1 pt), others (6 pts).

Results

In 13 pts with poorly differentiated NETs objective responses (OR) were: 3 PR (23%), 1 SD (7%), 9 PD (70%). Biochemical responses were 11%. In 27 patients with well-differentiated NETs the OR were: 8 PR (30%), 13 SD (48%) and 6 PD (22%). Biochemical and symptomatic responses were 20 and 50%, respectively.

Conclusions

The XELOX regimen is effective and tolerated in well-differentiated NETs after progression following somatostatin analogues.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Solcia E, Kloppel G, Sobin LH (2000) Histologic typing of endocrine tumours. WHO international histological classification of tumours. Springer, Berlin Heidelberg New York

    Google Scholar 

  2. Travis WD, Brambilla E, Muller-Hermelink HK, Harris SL (2004) Pathology and genetics of tumors of the lung, pleura, thymus and heart. IARC Press, Geneva

    Google Scholar 

  3. Bajetta E, Catena L, Procopio G, Bichisao E, Ferrari L, Della Torre S, De Dosso S, Iacobelli S, Buzzoni R, Mariani L, Rosai J (2005) Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment? Ann Oncol 16:1374–1380

    Article  PubMed  CAS  Google Scholar 

  4. Artale S, Giannetta L, Cerea G, Pedrazzoli P, Schiavetto I, Napolitano M, Veronese S, Bramerio E, Gambacorta M, Vanzulli A, Pisconti S, Pugliese R, Siena S (2005) Treatment of metastatic neuroendocrine carcinomas based on WHO classification. Anticancer Res 25:4463–4469

    PubMed  Google Scholar 

  5. Moertel CG, Kvols LK, O’Connell MJ, Rubin J (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in anaplastic variance of these neoplasm. Cancer 68:227–232

    Article  PubMed  CAS  Google Scholar 

  6. Fjallskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET, Eriksson BK (2001) Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 92:1101–1107

    Article  PubMed  CAS  Google Scholar 

  7. Rivera E, Ajani JA (1998) Doxorubicin, streptozotocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am J Clin 21:36–38

    Article  CAS  Google Scholar 

  8. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D (1992) Streptozocin–doxorubicin, streptozocin–fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519–523

    Article  PubMed  CAS  Google Scholar 

  9. Bajetta E, Ferrari L, Procopio G, Catena L, Ferrario E, Martinetti A, Di Bartolomeo M, Buzzoni R, Celio L, Vitali M, Beretta E, Seregni E, Bombardieri E (2002) Efficacy of chemotherapy combinations for the treatment of metastatic neuroendocrine tumours. Ann Oncol 13:614–621

    Article  PubMed  CAS  Google Scholar 

  10. Ridolfi R, Amaducci L, Derni S, Fabbri L, Innocenti MP, Vignutelli P (1991) Chemotherapy with 5-fluorouracil and streptozocin in carcinoid tumors of gastrointestinal origin: experiences with 13 patients. J Chemother 3:328–331

    PubMed  CAS  Google Scholar 

  11. Gonzalez MA, Biswas S, Clifton L, Corrie PG (2003) Treatment of neuroendocrine tumours with infusional 5-fluorouracil, folinic acid and streptozocin. Br J Cancer 89:455–456

    Article  PubMed  CAS  Google Scholar 

  12. Bajetta E, Zilembo N, Di Bartolomeo M, Di Leo A, Pilotti S, Bochicchio AM, Castellani R, Buzzoni R, Celio L, Dogliotti L (1993) Treatment of metastatic carcinoid and other neuroendocrine tumors with recombinant interferon alpha-2. Cancer 72:3099–3105

    Article  PubMed  CAS  Google Scholar 

  13. Tetzlaff ED, Ajani JA (2005) Oxaliplatin-based chemotherapy for the treatment of a metastatic carcinoid tumor. Int J Gastrointest Cancer 36:55–58

    Article  PubMed  Google Scholar 

  14. World Health Organization (1979) Handbook for reporting results of cancer treatment. WHO offset publication N. 48, Geneva

  15. Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufie P, Aparicio T, Aparicio T, Lasser P, Elias D, Duvillard P, Schlumberger M, Rougier P (1999) Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 81:1351–1355

    Article  PubMed  CAS  Google Scholar 

  16. Moertel CG, Kvols LK, O’Connell MJ, Rubin J (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: evidence of major therapeutic activity in anaplastic variance of these neoplasm. Cancer 68:227–232

    Article  PubMed  CAS  Google Scholar 

  17. Oberg K (2001) Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol 12(Suppl 2):S111–S114

    Article  PubMed  Google Scholar 

  18. Rougier P, Mitry E (2000) Chemotherapy in the treatment of neuroendocrine malignant tumors. Digestion 62:73–78

    Article  PubMed  CAS  Google Scholar 

  19. Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG (2005) Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group study E1281. J Clin Oncol 22:4897–4904

    Article  CAS  Google Scholar 

  20. Di Bartolomeo M, Bajetta E, Bochicchio AM, Carnaghi C, Somma L, Mazzaferro V, Visini M, Gebbia V, Tumolo S, Ballatore P (1995) A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) group. Ann Oncol 6:77–79

    PubMed  CAS  Google Scholar 

  21. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS (2006) Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24:401–406

    Article  PubMed  CAS  Google Scholar 

  22. Pavel ME, Baum U, Hahn EG, Hensen J (2005) Doxorubicin and streptozotocin after failed biotherapy of neuroendocrine tumors. Int J Gastrointest Cancer 35:179–185

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors would like to thank the Italian Trials in Medical Oncology (I.T.M.O.) group for technical assistance, Dr. Stefano Iacobelli (Università degli Studi “G. D’Annunzio”, Chieti, Italy) and Dr. Alfredo Falcone (Spedali Riuniti ASL 6, Livorno, Italy) for cooperation.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Emilio Bajetta.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bajetta, E., Catena, L., Procopio, G. et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?. Cancer Chemother Pharmacol 59, 637–642 (2007). https://doi.org/10.1007/s00280-006-0306-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-006-0306-6

Keywords

Navigation